Related Experiment Video
Updated: May 17, 2026
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
Everything you always wanted to know about CADY-mediated siRNA delivery* (* but afraid to ask)
Karidia Konate1, Anna Rydstrom, Gilles Divita
1Centre de Recherches de Biochimie Macromoleculaire, CRBM-CNRS, UMR-5237, UM1-UM2, University of Montpellier, Department of Molecular Biophysics and Therapeutics, 1919 Route de Mende, 34293 Montpellier, France.
Abstract:
Although siRNA consist in very promising therapeutics, their clinical development is limited by several biological barriers including low cellular permeability, poor stability and lack of tissue specificity. Therefore the Achilles' heel for siRNA-based therapy is directly related to the lack of efficient system to promote their delivery. During the last two decades, cell-penetrating peptides (CPPs) have been widely developed to enhance the cellular delivery of therapeutics. In this context we have elaborated a new strategy based on self-assembling peptide-based nanoparticles. The CADY peptide is a 20-residue secondary amphipathic peptide which is able to spontaneously self associate with siRNA with a strong affinity, by combining both electrostatic and hydrophobic interactions, to form stable nanoparticles. Investigations of both physico-chemical properties and cellular siRNA delivery revealed that the CADY/siRNA complexes were able to enter a wide variety of cell lines by a mechanism independent of any endocytotic pathway. In addition a deeper understanding of the self assembly of CADY molecules around siRNA leads to a "raspberry"-like nanoparticle architecture which provides new perspectives for the CADY/siRNA formulations. Finally the robustness of the biological response infers that peptide-based nanoparticle technology holds a strong promise for therapeutic applications. The present review deals with most of the biophysical characteristics as well as the cellular mechanism and cellular applications of CADY/siRNA nanoparticles.
Insights
New peptide nanoparticles efficiently deliver small interfering RNA (siRNA) therapeutics by overcoming cellular barriers. This self-assembling CADY peptide technology offers a promising platform for enhanced siRNA delivery and therapeutic applications.
Area of Science:
- Biotechnology
- Nanomedicine
- Molecular Biology
Background:
- Small interfering RNA (siRNA) therapeutics face challenges like poor cellular permeability, stability, and tissue specificity.
- Efficient delivery systems are crucial for the clinical development of siRNA-based therapies.
- Cell-penetrating peptides (CPPs) have emerged as tools to improve therapeutic cellular delivery.
Purpose of the Study:
- To develop a novel self-assembling peptide-based nanoparticle system for enhanced siRNA delivery.
- To characterize the physico-chemical properties and cellular uptake mechanisms of these nanoparticles.
- To explore the therapeutic potential of peptide-nanoparticle formulations for siRNA delivery.
Main Methods:
- Utilized the CADY peptide, a 20-residue amphipathic peptide, for self-assembly with siRNA.
- Investigated the formation of stable CADY/siRNA nanoparticles through electrostatic and hydrophobic interactions.
- Assessed nanoparticle properties and cellular delivery across various cell lines.
- Analyzed the cellular uptake mechanism, independent of endocytosis.
Main Results:
- CADY peptide spontaneously self-assembles with siRNA into stable nanoparticles.
- CADY/siRNA nanoparticles demonstrate efficient cellular entry in diverse cell lines.
- Uptake mechanism is independent of endocytotic pathways.
- Nanoparticle architecture exhibits a "raspberry"-like structure, offering formulation advantages.
Conclusions:
- Peptide-based nanoparticle technology, exemplified by CADY/siRNA, holds significant promise for overcoming siRNA delivery barriers.
- The self-assembling nature and efficient cellular penetration suggest robust therapeutic potential.
- This approach provides new perspectives for developing advanced siRNA formulations for therapeutic applications.
More Related Videos
08:31Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers